CD44v6-specific CAR gene-engineered T cell therapy (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug NameCD44v6-specific CAR gene-engineered T cell therapy (Shenzhen Geno-Immune Medical Institute)
Drug Alias NameCD44v6-specific CAR gene-engineered T cells4SCAR-CD44v64SCAR-CD44v6 T Cell Therapy4SCAR-CD44v6
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionCD44 antigen modulatorsT lymphocyte replacements
TargetsCD44 antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShenzhen Geno-Immune Medical Institute
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A